MiMedx Group, Inc.

MiMedx Group, Inc. Earnings Recaps

MDXG Health Care 2 recaps
Next earnings: February 24, 2027 (estimated) · full calendar
Q3 2026 Oct 30, 2026

MiMedx reported mixed third-quarter trends: Surgical sales grew, while Wound Care remained pressured by Medicare reimbursement changes. The stock rose 0.5% after earnings, a roughly flat reaction.

Key takeaways
  • Net sales were $62 million; Surgical revenue increased 9% year over year, with volume up in the mid-teens.
  • Management said Surgical growth would have been in the mid-teens excluding nearly $1 million of prior-year opportunistic sales that did not recur and higher rebate adjustments tied to promotional activity.
  • Wound Care continued to face pricing pressure, lower market volume and disruption from 2026 Medicare reimbursement changes; Wound Care Center volume grew 7% sequentially.
  • GAAP gross margin was 80%, up 11 percentage points sequentially; adjusted EBITDA was $2 million, a $10 million sequential improvement.
  • MiMedx announced a $25 million settlement and licensing agreement with one party it says infringed its patents, while two other cases remain in litigation; the Sanara acquisition faces an extended FTC review.
Q2 2026 Jul 31, 2026

Shares declined 2.1% following Q2 results and acquisition news as investors likely digested ongoing challenges in wound care despite surgical growth and the transformational Sanara MedTech deal.

Key takeaways
  • Surgical revenue grew 15% year-over-year, continuing momentum from prior quarters.
  • Overall company revenue rose 9% sequentially from Q1 to Q2.
  • Wound care remains under pressure due to Medicare reimbursement changes causing market disruption.
  • The Sanara MedTech acquisition (~$35/share) will shift MiMedx's revenue mix to 75% surgical and 25% wound post-close.
  • Expected 2027 combined company revenue above $400 million with double-digit growth and adjusted EBITDA margin exceeding 20%, driven by $20 million in cost synergies.